Varex Imaging Corporation (VREX)

Executive Summary / Key Takeaways

• Industrial Segment Driving Margin Expansion: Varex's Industrial segment grew 17.4% year-over-year in Q1 FY26 with 36.7% gross margins, materially outpacing the Medical segment's flat growth and 31.8% margins. This mix shift toward higher-margin, faster-growing cargo inspection systems and components creates a structural tailwind for consolidated profitability, with management targeting 38-40% Industrial margins as service revenue ramps.

• India Regionalization as Strategic Moat: The operational Vizag detector factory and upcoming Pune tube facility represent more than cost mitigation—they establish a low-cost manufacturing base for value-tier radiographic components that can compete with Asian rivals while insulating Varex from US-China tariff volatility. This $55M+ investment is impacting near-term P&L but building a defensible position in emerging markets and providing customers with critical local content.

• Balance Sheet Repair Enhances Flexibility: The March 2026 debt refinancing reduced outstanding debt by $18M and will cut annual interest expense by over $7M, while extending maturities to 2031. This strengthens Varex's ability to fund the India expansion and photon counting R&D without diluting shareholders, improving financial resilience amid geopolitical uncertainty.

• Tariff Mitigation Demonstrates Operational Agility: Despite 100-150 basis points of gross margin pressure from US-China tariffs, Varex is passing through most costs to customers and regionalizing supply chains. The indefinite suspension of MOFCOM investigations removes a major overhang, and Chinese customers have resumed ordering as tariff rates normalized, suggesting Q3 FY25's $20M revenue impact was temporary.

• Key Risks Center on Execution and Concentration: With 52% of revenue from the top 10 customers and one customer representing 16% of sales, Varex faces meaningful customer concentration risk. Success hinges on flawless execution of the India ramp, photon counting commercialization with two anchor OEMs, and maintaining pricing power in Medical amid intense competition from vertically integrated OEMs.

Setting the Scene: The X-Ray Imaging Component Oligopoly

Varex Imaging Corporation, incorporated in 2016 as a spin-off from Varian Medical Systems (VAR), operates as a critical bottleneck in the global medical and industrial imaging supply chain. The company designs and manufactures the high-value components that make X-ray imaging possible: tubes that generate X-rays, digital detectors that capture them, and the associated software and subsystems that process images. These aren't commodity parts—each CT tube represents $15,000-$50,000 in value, requires precision manufacturing, and must withstand extreme heat and mechanical stress while delivering consistent performance. Replacement cycles vary dramatically: US CT tubes last 2-6 years, but high-utilization Chinese systems require replacement every 10-20 months, creating a recurring revenue stream that underpins Varex's installed base of over 170,000 tubes and 170,000 detectors.

The industry structure resembles a specialized oligopoly. Varex holds an estimated 35% global market share in X-ray tubes, competing against diversified giants like Canon Medical Systems (CAJ) and Thales Group (HO), while facing specialized industrial players like Comet Holding (COTN) in accelerators. The Medical segment serves OEM customers who integrate components into CT scanners, mammography systems, and fluoroscopy equipment—customers who increasingly compete with Varex by manufacturing components in-house. The Industrial segment sells to security agencies for cargo screening and manufacturers for nondestructive testing, where Varex's vertically integrated systems command premium pricing. This dual-segment structure provides diversification but also exposes Varex to different competitive dynamics: Medical faces pricing pressure from OEM insourcing and Asian competitors, while Industrial benefits from tender-driven government demand and higher service margins.

Varex's strategic positioning has evolved through deliberate capital allocation. The 2020 issuance of $300M in 7.875% Senior Secured Notes funded capacity expansion, while the recent 2026 refinancing at lower rates signals balance sheet normalization. The 2015 acquisition of 73.5% of MeVis Medical added software capabilities, and the 2018 formation of VEC Imaging GmbH joint venture aimed at technology development. These moves established the foundation for Varex's current push toward integrated modality-based solutions rather than standalone components—a shift that increases customer stickiness and average contract value by solving complete imaging chain problems rather than selling discrete parts.

Technology, Products, and Strategic Differentiation

The Industrial Cargo Systems Moat

Varex's cargo inspection systems business represents the company's most compelling technological and economic moat. In fiscal 2025, the company booked over $55 million in orders and shipped more than 15 systems to countries including Mexico, Iraq, Brazil, and Saudi Arabia. This is a vertically integrated systems play where Varex manufactures the Linatron linear accelerator (the X-ray source), detector arrays, image processing software, and electromechanical framework in-house. This integration eliminates margin stacking from component suppliers, reduces system integration risk for customers, and creates a 12-18 month installation cycle that locks out competitors. Once installed, these systems generate service revenue for 2-3 years post-commissioning at margins potentially reaching 38-40% as warranties expire.

The Q3 FY25 order intake of $17 million brought year-to-date bookings to over $55 million, with a typical system price exceeding $3 million. This business benefits directly from global security spending and the shift toward automated screening at ports and borders. Unlike Medical components that face replacement pressure, cargo systems create installed base lock-in—customers can't easily switch accelerator technology without replacing entire gantries. Varex's UK facility in Stoke-on-Trent serves as the systems integration hub, while the Las Vegas plant provides components, creating a geographic hedge against regional disruptions. The company is ramping UK production and investing in demonstration capabilities, suggesting confidence in a robust pipeline that could drive Industrial segment revenue beyond the 10% FY25 growth rate.

Photon Counting: Democratizing Next-Generation CT

Varex's photon counting detector program represents a calculated bet on technology diffusion. While early entrants target the ultra-high-end CT market, Varex aims to "democratize this technology" across the broader CT spectrum. The company has two OEMs "knee deep in product commercialization" and others evaluating the technology, with the THOR linear array detector already released for high-speed industrial CT imaging in Q3 FY25. The high-end CT market is small and crowded; the mid-tier and value segments represent substantially larger volume opportunities where Varex's cost structure and OEM relationships provide advantage.

The collaboration with Technical University of Munich to showcase a photon counting CT system in 2026 serves multiple strategic purposes. It demonstrates Varex's ability to integrate multiple proprietary components—high-power CT tubes optimized for photon counting, high-voltage generators, connectors, and heat exchangers—into a complete subsystem. This integrated approach reduces OEM development time and risk, making Varex's solution more attractive than competitors offering discrete detectors. Success here could unlock a $150 million revenue opportunity by 2029 (two-thirds medical, one-third industrial), representing nearly 18% of FY25 revenue. The risk is that commercialization timelines slip or OEMs adopt alternative technologies, leaving Varex with stranded R&D investment.

India Manufacturing: The Cost and Geopolitical Hedge

The India expansion strategy addresses two critical vulnerabilities simultaneously: cost competition from Asian manufacturers and tariff exposure from US-China trade tensions. The Vizag detector factory is operational and shipping radiographic detectors globally, while the Pune tube factory will begin shipments in 12-15 months. This is not simple labor arbitrage; Varex is establishing a complete value-tier supply chain that can serve India, South Asia, Latin America, and Africa, regions where Chinese OEMs are expanding. This regionalization provides customers with "local content" that satisfies procurement preferences and avoids import duties, while giving Varex a cost structure competitive with Asian rivals in markets representing future growth.

The strategy directly targets radiography share loss Varex has experienced over time. The Lumen family of detectors, combined with Nexus software, offers competitive performance at pricing manufactured in India. This matters because radiography represents high-volume, price-sensitive demand where Varex's traditional US-based cost structure couldn't compete. By Q1 FY26, the India facility was already shipping globally, validating the operational model. The near-term P&L burden from ramp-up costs and inventory build is an intentional investment to capture share in a $500M+ addressable market.

Financial Performance & Segment Dynamics: Evidence of Strategic Pivot

The Mix Shift Story in Numbers

Varex's Q1 FY26 results provide evidence of the Industrial-led growth thesis. Total revenue of $210 million grew 5% year-over-year, but the composition reveals the strategic inflection. Industrial segment revenue of $64.8 million surged 17.4% (+$9.6M), while Medical segment revenue of $144.8 million was essentially flat (+0.1%, +$0.2M). More importantly, Industrial gross profit increased 25.3% (+$4.8M) with a 36.7% gross margin, while Medical gross profit declined 7.1% (-$3.5M) with a 31.8% margin. This divergence demonstrates that Industrial growth is not only faster but also more profitable, and that Medical faces cost headwinds—notably $6.8M in increased material costs—that are compressing margins despite stable volumes.

The full-year FY25 picture reinforces this trend. Industrial revenue of $252 million grew 10% year-over-year, with the security vertical increasing to 41% of segment sales from 40% in FY24. Medical revenue of $593 million grew only 2%, with CT representing 40% of medical revenue but facing pricing pressure and tariff impacts. The consolidated gross margin masks a 500-basis-point spread between segments, suggesting that every percentage point of mix shift toward Industrial adds approximately $2.5M in incremental gross profit at current revenue levels. Management's commentary that Industrial margins could return to 38-40% as service revenue ramps implies potential for 300-400 basis points of segment margin expansion over the next 18-24 months.

Balance Sheet: Funding the Transformation

Varex's March 2026 debt refinancing represents a critical enabler for the strategic pivot. The company replaced $368 million of 7.875% Senior Secured Notes due 2027 with a $350 million term loan, $100 million revolver, and $40 million delayed draw facility at SOFR + 2.50% (with SOFR fixed at 3.65% via swap). The transaction used $42M in cash but will save over $7M annually in interest expense while extending maturities to 2031. This reduces annual cash interest from approximately $29-30M to the low-$20M range, freeing up capital to fund India expansion and photon counting R&D without sacrificing financial flexibility.

The balance sheet shows intentional inventory buildup to $328 million (up $29M in Q1 FY26), representing 214 days of inventory—34 days higher than prior year. Management explicitly states this is intentional, preparing for cargo system ramps, India factory qualification, and anticipated Industrial demand. While this consumes working capital (operating cash flow was -$16M in Q1), it positions Varex to capture revenue without supply constraints. The strong Industrial order pipeline and customer deposits on cargo systems mitigate the risk of demand disappointment.

Net debt of $244 million against trailing twelve-month adjusted EBITDA of $127 million yields a leverage ratio of 1.9x, well within comfortable ranges for an industrial technology company. The company's target gross debt range of $300-350M suggests further deleveraging is planned, which would improve interest coverage and reduce financial risk. With $126M in cash and $100M undrawn revolver, liquidity is adequate to fund the India investment cycle while maintaining operational buffer.

Outlook, Management Guidance, and Execution Risk

FY26 Trajectory: Industrial-Led Growth with Medical Stability

Management's guidance for Q2 FY26 calls for revenue of $210-225 million and non-GAAP EPS of $0.15-0.25, with full-year expectations for both Medical and Industrial segments to grow. The China market is modeled as flattish to minor growth due to tariff uncertainties, but management emphasizes that headwinds faced in fiscal year 2024 are now behind them for Medical. This stability suggests the 150-200 basis points of tariff-related gross margin pressure is manageable and that customer relationships remain intact despite geopolitical tensions.

The Industrial segment's outlook is more dynamic. Management notes potential for double-digit growth, contingent on winning cargo system orders and timely customer acceptance. The $55M+ in FY25 cargo orders provides a baseline, but the pipeline of tenders could drive significant upside. The key variable is conversion velocity—cargo systems have 12-18 month installation cycles, so orders won in early FY26 may not revenue until late FY26 or FY27.

Photon Counting and India: Long-Term Catalysts with Near-Term Burden

Management's photon counting timeline remains measured. Two OEMs are "knee deep in product commercialization" with revenue potential as early as FY27, but the technology is still in the new platform introduction process. The $150M revenue target by 2029 represents a 60% increase over FY25 Industrial revenue, requiring successful market penetration beyond the high-end segment. Success would diversify Varex away from traditional X-ray tubes into higher-value digital detectors, improving overall margins and reducing cyclicality.

The India factories are proceeding as planned, but the tubes factory won't ship for 12-15 months. Management acknowledges the India operations currently represent a burden on P&L due to ramp costs and inventory, but views this as essential investment. The critical execution milestone is qualifying Indian suppliers to reduce procurement costs and accelerate localization. If Varex can achieve cost parity with Asian competitors on radiography detectors by FY27, it could recapture meaningful share in a market where it has lost ground over the years.

Risks and Asymmetries: What Could Break the Thesis

Customer Concentration: The 16% Elephant in the Room

Varex's disclosure that one customer represented 16% of Q1 FY26 revenue, with the top 10 accounting for 52%, represents a material risk. Management notes the vast majority of those top 10 customers are medical. A single OEM decision to insource tube production or switch suppliers could create a $30-40M revenue hole that would take years to fill through Industrial growth. The risk is amplified in China, where domestic OEMs are increasingly focused on commercial activities outside of China and may pressure Varex on pricing to compete globally.

The mitigating factor is component customization. It can be costly and complex for customers to switch to another provider because tubes and detectors are engineered for specific equipment. However, this stickiness has limits—Canon and other large OEMs already manufacture components in-house, and if they expand vertical integration, Varex's share could erode gradually.

Tariff and Geopolitical Whipsaw

While MOFCOM investigations are suspended indefinitely, the underlying risk remains. If US-China trade tensions escalate again, Varex faces a 150-200 basis point gross margin headwind that cannot be fully mitigated. Management's strategy of passing through most tariff costs works when rates are 55%, but faced challenges when rates spiked to 145% in Q3 FY25, causing customers to pause shipments. This demonstrates that Varex's pricing power has ceilings. The company's 17% revenue exposure to China means any resumption of the trade war could create another $15-20M quarterly revenue swing.

Legal and Supply Chain Entanglements

The VEC Imaging GmbH joint venture dispute, ongoing since August 2023, creates contingent liability. If either party prevails, the winner must buy the other's 50% interest at 75% of fair market value. German joint venture valuations for imaging technology firms typically range $20-40M, implying a potential $15-30M cash outlay. This represents an unmodelled liability that could consume capital otherwise allocated to India expansion or debt reduction.

Supply chain concentration poses additional risk. Varex sources critical components like transistor arrays, cesium iodide coatings , and X-ray tube targets from a limited group of suppliers. Any disruption could halt production of high-margin CT tubes. The company is accelerating qualifying suppliers from India to diversify, but this is a multi-year process.

Valuation Context: Pricing in Execution, Not Perfection

At $10.78 per share, Varex Imaging trades at an enterprise value of $727.59 million, representing 0.85x trailing twelve-month revenue of $844.6 million and 7.49x adjusted EBITDA of $127 million. These multiples place Varex at a discount to diversified industrial technology peers like Canon but premium to specialized players like Comet. This valuation suggests the market is pricing Varex as a stable but low-growth component supplier, potentially overlooking the margin expansion from Industrial mix shift and the strategic optionality of the India regionalization strategy.

The price-to-sales ratio of 0.53x and price-to-book of 0.95x indicate skepticism about Varex's ability to generate returns above cost of capital, particularly given the -12.90% ROE (distorted by the $93.9M goodwill impairment in Q3 FY25). However, excluding non-cash charges, the company's return on assets of 3.62% and operating margin expansion from 7% to 9% in Q1 FY26 demonstrate improving operational efficiency. The key valuation driver will be whether Varex can achieve management's targeted Industrial segment margins of 38-40% while growing the segment double-digits.

The debt refinancing improved the capital structure, reducing annual interest expense from ~$29M to the low-$20M range, which adds approximately $0.12-0.15 to annual EPS. With net debt/EBITDA at 1.9x and management targeting gross debt of $300-350M, Varex has capacity to fund the India expansion internally while maintaining financial flexibility.

Conclusion: Two Variables Determine the Thesis

Varex Imaging's investment thesis hinges on the velocity of Industrial segment margin expansion and the successful ramp of India manufacturing to drive Medical segment share gains. The Q1 FY26 results provide early validation—Industrial revenue growth of 17.4% with 36.7% gross margins, combined with the debt refinancing that frees up $7M+ in annual cash flow, creates a pathway to sustained earnings growth. If cargo systems service revenue begins to materialize in mid-2026 as projected, Industrial margins could approach 40%, adding 200-300 basis points to consolidated EBITDA margins.

The India strategy addresses the core vulnerability in Medical: cost competitiveness in radiography. The Vizag factory's global shipments and the Pune tube facility's 12-15 month timeline suggest Varex could recapture lost share in value-tier markets where Asian competitors have dominated. However, the execution burden is substantial—qualifying suppliers, maintaining quality, and convincing OEMs to redesign around Indian-made components requires flawless operational performance.

The stock's valuation at 0.85x revenue and 7.49x EBITDA embeds modest expectations, creating upside asymmetry if the Industrial mix shift accelerates and India delivers on its promise. Conversely, customer concentration risk and potential OEM insourcing represent downside scenarios. Monitoring cargo systems order intake, India factory qualification milestones, and Chinese OEM design win announcements will provide the clearest signals of whether Varex is successfully transforming into a higher-margin, geographically resilient imaging solutions provider.